Abstract:Glioblastoma (GBM) tumors respond poorly to nearly all cancer therapies due to their highly immunosuppressive tumor microenvironment (TME). Hypoxia exacerbates this immunosuppression by upregulating the hypoxia-inducible factor (HIF) pathway in glioma-associated myeloid cells (GAMs) which suppressively polarizes them to maintain this immune "cold" state. This hypoxia-driven programming inhibits CD8+ T cell infiltration and effector function by inducing metabolic dysfunction, thereby increasing resistance to chemotherapy and T cell immune checkpoint blockade (ICB). Targeting hypoxia thus emerges as a promising strategy to overcome such resistance. Our study suggests that GBM hypoxia ablation can convert the immunosuppressive tumor microenvironment into a more pro-inflammatory one. Tumor hypoxia ablation using the hypoxia-activated prodrug Evofosfamide significantly enhances survival in both GL261 (p<0.0001) and the checkpoint blockade-resistant CT2A murine GBM models (p<0.01). Evofosfamide treatment boosts tumor infiltrating Ki67+ proliferative CD8+ T cells (p<0.001) and heightens cytotoxicity, indicated by increased Granzyme B expression (p<0.01). It also reduces the co-expression of exhaustion markers LAG-3 and TIM-3 (p<0.001), signaling decreased T cell exhaustion. Antigen-specific CD8+ T cells from Evofosfamide-treated primary GBM tumors exhibit enhanced ex vivo killing capacity when co-cultured with GL261-OVA cells (p<0.001). Furthermore, Evofosfamide enhances microglia proliferation and repolarizes them towards a pro-inflammatory state, marked by upregulation of M1 markers such as CD80 (p<0.001) and downregulation of M2 markers like Arginase (p<0.05). Hypoxia reduction also increases chemotherapy sensitivity, synergistically improving survival when combined with the blood-brain barrier-penetrating, immunogenic chemotherapy Berubicin (CT2A; vehicle MS=26d, Evo MS=36d, Berubicin MS=55d, Combo MS=70.5d). Future research will investigate the mechanisms underlying this shift towards a pro-inflammatory state, focusing on metabolic changes in CD8+ T cells and the impact of altered HIF pathway signaling on GAM polarization following hypoxia ablation. Understanding the therapeutic potential of reversing hypoxia-mediated immunosuppression could lead to novel combination therapies capable of overcoming resistance to both chemotherapy and immunotherapy in GBM.

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy.

Glioma-derived small extracellular vesicles induce pericyte-phenotype transition of glioma stem cells under hypoxic conditions

Hypoxia upregulates HIG2 expression and contributes to bevacizumab resistance in glioblastoma

Novel insights into astrocyte-mediated signaling of proliferation, invasion and tumor immune microenvironment in glioblastoma

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma

Single-cell RNA sequencing identifies critical transcription factors of tumor cell invasion induced by hypoxia microenvironment in glioblastoma

Autophagy activation promotes bevacizumab resistance in glioblastoma by suppressing Akt/mTOR signaling pathway

Tmic-20. Unlocking The Potential Of Hypoxia Reduction In Reshaping The Glioblastoma Tumor Microenvironment For Enhanced Therapeutic Synergy

Stem-07. Unveiling The Role Of Hypoxia And Tam-Secreted Tgf-Β1 In Promoting Glioma Stem Cell Maintenance Via Yap/Taz Activation In Glioblastoma Peri-Necrotic Niche

GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance

Increased oxygen stimulation promotes chemoresistance and phenotype shifting through PLCB1 in gliomas

P11.30 Special VEGF90kDa form in exosome from GBM cells activates TAZ in endothelial cells to promote angiogenesis and contributes bevacizumab resistance

Bevacizumab Promotes Active Biological Behaviors Of Human Umbilical Vein Endothelial Cells By Activating Tgf Beta 1 Pathways Via Off-Vegf Signaling

Multiprong control of glioblastoma multiforme invasiveness: blockade of pro-inflammatory signaling, anti-angiogenesis, and homeostasis restoration

Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme

Hypoxia-induced TGFBI maintains glioma stem cells by stabilizing EphA2

Hypoxia-Driven M2-Polarized Macrophages Facilitate Cancer Aggressiveness and Temozolomide Resistance in Glioblastoma

The Hippo-TAZ axis mediates vascular endothelial growth factor C in glioblastoma-derived exosomes to promote angiogenesis

Investigating Glioblastoma Response to Hypoxia

Hypoxia-Induced Autophagy Is Involved in Radioresistance via HIF1A-Associated Beclin-1 in Glioblastoma Multiforme

Modulation of blood-tumor barrier transcriptional programs improves intra-tumoral drug delivery and potentiates chemotherapy in GBM